241 related articles for article (PubMed ID: 20099988)
1. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.
Wong SL; Goldberg MR; Ballow CH; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Feb; 30(2):136-43. PubMed ID: 20099988
[TBL] [Abstract][Full Text] [Related]
2. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.
Ma JD; Lawendy NM; Fullerton T; Snyder PJ; Nafziger AN; Bertino JS
Int J Clin Pharmacol Ther; 2009 Feb; 47(2):111-9. PubMed ID: 19203567
[TBL] [Abstract][Full Text] [Related]
7. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
8. The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.
Paulson SK; Wood-Horrall RN; Hoover R; Quintas M; Lawrence LE; Cammarata SK
Clin Ther; 2017 Jun; 39(6):1182-1190. PubMed ID: 28495029
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.
Wong SL; Sörgel F; Kinzig M; Goldberg MR; Kitt MM; Barriere SL
J Clin Pharmacol; 2009 Jul; 49(7):816-23. PubMed ID: 19443680
[TBL] [Abstract][Full Text] [Related]
10. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
Wong SL; Barriere SL; Kitt MM; Goldberg MR
J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659
[TBL] [Abstract][Full Text] [Related]
13. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
14. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.
Rogers JF; Morrison AL; Nafziger AN; Jones CL; Rocci ML; Bertino JS
Clin Pharmacol Ther; 2002 Dec; 72(6):711-7. PubMed ID: 12496752
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
16. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Ibrahim A; Karim A; Feldman J; Kharasch E
Anesth Analg; 2002 Sep; 95(3):667-73, table of contents. PubMed ID: 12198057
[TBL] [Abstract][Full Text] [Related]
17. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
18. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers.
Volak LP; Hanley MJ; Masse G; Hazarika S; Harmatz JS; Badmaev V; Majeed M; Greenblatt DJ; Court MH
Br J Clin Pharmacol; 2013 Feb; 75(2):450-62. PubMed ID: 22725836
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
